This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Reply to “Prescribing Benzodiazepines for Patients With Substance Use Disorders”

Robin E. Clark, PhD; Haiyi Xie, PhD; Mary F. Brunette, MD

Published: November 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We agree with Dr. Lieberman’s concern that precipitate intervention by policymakers might restrict appropriate use of benzodiazepines. That concern is clearly identified in our conclusions, in which we state, "It would be a mistake to adopt overly restrictive prescription policies." The larger question is, what, if any, role should government play in addressing the apparent discrepancy between guidelines developed by physicians and actual prescribing practice? Dr. Lieberman suggests that physicians can do better without policymakers’ involvement.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 65

Quick Links: Addiction , Substance Use Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...